Aureobasidium Pullulans β-glucan Investigated for Musculoskeletal Function in Sarcopenic Adults
Background
Sarcopenia is a progressive loss of muscle mass, strength, and function, common in aging, leading to frailty and reduced quality of life. Current interventions often involve exercise and protein supplementation, but novel therapeutic strategies are needed to effectively combat muscle wasting. Aureobasidium pullulans produced β-glucan has shown promise in preliminary human studies for increasing muscle mass and strength in the elderly, suggesting a potential role in improving musculoskeletal health. This trial aimed to further elucidate its effects.
Study Design
Investigators conducted a randomized, double-blind, placebo-controlled trial over 12 weeks in adults diagnosed with relative sarcopenia. Participants were assigned to receive either Aureobasidium pullulans produced β-glucan or a placebo. The study also included regular combined exercise for all participants. Primary endpoints included changes in muscle strength, muscle mass, and overall muscle function, assessed at baseline and throughout the intervention period to evaluate the compound's efficacy.
Why It Matters
If positive, this trial could validate Aureobasidium pullulans β-glucan as a novel nutritional strategy for combating sarcopenia, offering a non-pharmacological option to complement exercise. For individuals facing age-related muscle decline, a safe and effective supplement could significantly improve quality of life and reduce frailty risks. This research explores a new avenue beyond traditional protein and resistance training, potentially expanding the toolkit for clinicians and biohackers targeting musculoskeletal health. The combination with exercise highlights a synergistic approach, suggesting that future protocols might integrate specific nutritional support with physical activity for optimal outcomes.
aureobasidium pullulans beta-glucan
sarcopenia
muscle strength
muscle mass
musculoskeletal function
randomized controlled trial